TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02385071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo
Study: NCT02385071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 0.5 mg
Description: Inhaled Staccato alprazolam 0.5 mg + oral placebo
Study: NCT03914690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
Study: NCT00865748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 500 mg tablets, single dose
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOPHAGE® XR 500 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT01418456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotics
Description: A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
Study: NCT01040247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo Transfer
Description: In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo Transfer
Description: In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
Study: NCT04459728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 2: Mindfulness
Description: Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 3 - Sleep Hygiene
Description: Daily wellness element focusing on sleep hygiene; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 4 - Social Connectedness
Description: Daily wellness element focusing on social connectedness; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 5 - Nutrition
Description: Daily wellness element focusing on nutrition; adherence documented online daily
Study: NCT04189484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 21 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 35 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 70 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 15 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 25 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 50 mg administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 100 mg administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered SC
Study: NCT00642044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Crosslinking
Description: UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
Study: NCT03454035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
Study: NCT00557440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate / mometasone furoate
Description: Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate / mometasone furoate
Description: Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate / mometasone furoate
Description: Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol/mometasone
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol/mometasone
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol/mometasone
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to fluticasone propionate/salmeterol
Description: Placebo to fluticasone propionate / salmeterol delivered via MDDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to fluticasone propionate/salmeterol
Description: Placebo to fluticasone propionate / salmeterol delivered via MDDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to fluticasone propionate/salmeterol
Description: Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
Study: NCT01662206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
Study: NCT04459728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 6 - Wellness Exercises
Description: Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 7 - Motivational Messages
Description: Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
Study: NCT04590131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
Description: Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
Description: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
Study: NCT00675948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-2000-02
Description: Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
Study: NCT05043909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based training
Description: Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
Study: NCT03342963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01
Description: Aripiprazole 3 mg/sertraline 100 mg combination drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01
Description: Aripiprazole 3 mg/sertraline 100 mg combination drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01
Description: Aripiprazole 3 mg/sertraline 100 mg combination drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01
Description: Aripiprazole 3 mg/sertraline 100 mg combination drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and sertraline
Description: Aripiprazole 3 mg and sertraline 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and sertraline
Description: Aripiprazole 3 mg and sertraline 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and sertraline
Description: Aripiprazole 3 mg and sertraline 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and sertraline
Description: Aripiprazole 3 mg and sertraline 100 mg
Study: NCT01667484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall XR 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall XR 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01760720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT CARE
Study: NCT04558944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporal Shock Wave Therapy
Description: Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
Study: NCT01476956

Intervention type: OTHER
Intervention: Observational study
Description: RA patients on standard DMARD therapy
Study: NCT00816296

Intervention type: OTHER
Intervention: Blood Draw
Description: 2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.

Intervention type: OTHER
Intervention: Blood Draw
Description: 2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.

Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.

Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.

Intervention type: OTHER
Intervention: BodPod Measurement
Description: Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.

Intervention type: OTHER
Intervention: BodPod Measurement
Description: Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.

Intervention type: OTHER
Intervention: Liver Ultrasound
Description: A liver ultrasound will be performed at study entry and 6 months after study entry.

Intervention type: OTHER
Intervention: Liver Ultrasound
Description: A liver ultrasound will be performed at study entry and 6 months after study entry.
Study: NCT03597880

Intervention type: OTHER
Group type: OTHER
Intervention: obese patients
Description: underwent bariatric surgery
Study: NCT03922126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer counseling
Description: Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer counseling
Description: Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV/STI self-testing kits
Description: Kits to self-test for HIV/STIs
Study: NCT03155971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon
Description: SeQuent ® Please; B.Braun, Melsungen, Germany
Study: NCT01236482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin versus oxytocin-ergometrine
Description: Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin versus oxytocin-ergometrine
Description: Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
Study: NCT02459301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Study: NCT01655771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 Dose 2
Study: NCT01662206

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily containing 348.25 mg of potato starch
Study: NCT03401866

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DSC-MRI
Description: The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes.
Study: NCT04626934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific cognitive intervention
Description: The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional occupational therapy treatment
Description: The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
Study: NCT01115504

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: 300 mg daily for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 300 mg daily for 30 days
Study: NCT01006148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenix Plus
Description: It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
Study: NCT03527667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
Study: NCT01164826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabumetone
Description: Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relafen
Description: Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
Study: NCT00659022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate surgery (resection of primary colorectal tumor)
Description: no neo-adjuvant treatment, immediate surgery
Study: NCT00562835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline intravenously and vitamin B1 per os
Description: Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
Study: NCT02577549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Participants will attend exercise and diet classes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
Study: NCT00762229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg
Description: Ezetimibe 10 mg daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg
Description: Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half